The United States Patent and Trademark Office (USPTO) has granted patent US12582609B2 to ModernaTX, Inc. The patent, titled "Cancer vaccines," relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using and compositions comprising these vaccines. The filing date for this application was October 21, 2016, and the patent was granted on March 24, 2026, with 36 claims.

This patent grant represents the formal recognition of intellectual property for Moderna's cancer vaccine technology. For compliance officers, this is primarily an informational update regarding a competitor's or partner's intellectual property status. There are no immediate compliance obligations or actions required for regulated entities based solely on this patent grant, other than awareness of the IP landscape.